European public assessment reports

  • Email
  • Help

This page allows you to find the European public assessment reports (EPAR) for human medicines published by the European Medicines Agency (EMA).

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

Use this search to find information including a public-friendly summary in question-and-answer format and the package leaflet. You can also find information on medicines that have been refused a marketing authorisation or that have been suspended or withdrawn after being approved.

As of October 2016, EMA publishes the clinical data submitted by pharmaceutical companies to support their marketing applications for human medicines under the centralised procedure, allowing the public to better understand the Agency’s decision-making. For more information see clinical data publication.

The Agency does not evaluate all medicines currently in use in Europe. If you cannot find the medicine you need through this search, please visit the website of your national health authority.

More information is available on the Central authorisation procedure and in EPARs: background and context.

Document status

Include:

Browse by letter

Browse by letter for medicines that have a European Public Assessment Report:

Or for other types of content pick from the navigation on the left.

Search by keyword

Search for keyword:

Search by therapeutic area

Browse the database based on therapeutic area:

/

Browse by type

Browse by type:

Download results to spreadsheet
EPAR Search results
Name Active substance Therapeutic area Date of authorisation / refusal Additional monitoring Orphan     Has current safety alert Status
Avaglim

rosiglitazone / glimepiride

Diabetes Mellitus, Type 2 2006-06-27           Withdrawn
Avandamet

rosiglitazone / metformin hydrochloride,

Diabetes Mellitus, Type 2 2003-10-20           Withdrawn
Avandia

rosiglitazone

Diabetes Mellitus, Type 2 2000-07-11           Withdrawn
Nyracta

rosiglitazone

Diabetes Mellitus, Type 2 2000-07-11           Withdrawn
Venvia

rosiglitazone

Diabetes Mellitus, Type 2 2000-07-11           Withdrawn